HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmasset: A Breakout Year But Big Catalysts Lie Ahead

Executive Summary

Although only half over, 2011 already has been pivotal for hepatitis C drug development, with the launch of two paradigm-shifting protease inhibitors, Johnson & Johnson/Vertex Pharmaceuticals Inc.'s Incivek (telaprevir) and Merck & Co.'s Victrelis (boceprevir). Both hit the market in May, even as attention is now shifting to the next big advance in HCV. Based on its work on next-gen HCV treatment, Pharmasset, Inc. has captivated the investment community.
Advertisement

Related Content

Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo
Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
How Does Pharmasset’s PROTON Data Compare To Other HCV Candidates?
EASL Preview: Dual Versus Quad Combinations
Bristol, Pharmasset To Study Oral HCV Regimen Together
J&J, Vertex Partner To Commercialize VX-950 For Hepatitis C

Topics

Advertisement
UsernamePublicRestriction

Register

PS053582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel